FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043973417> ?p ?o ?g. }

• W2043973417 endingPage "239" @default.
• W2043973417 startingPage "239" @default.
• W2043973417 abstract "Clinical potential of lurasidone in the management of schizophrenia Ludovic Samalin, Marion Garnier, Pierre-Michel LlorcaCentre Hospitalier Universitaire, Clermont-Ferrand, FranceAbstract: Lurasidone is a new second-generation antipsychotic approved in October 2010 by the Food and Drug Administration for the treatment of schizophrenia. Like other second-generation antipsychotics, lurasidone is a powerful antagonist of D2 dopamine and 5HT2A serotonin receptors, but differs from the other second-generation antipsychotics in its action profile for certain receptors. Lurasidone is the second-generation antipsychotic with the greatest affinity for 5HT7 receptors and has a high affinity for 5HT1A serotonin receptors, compatible with favorable effects on cognitive function and an antidepressant action. By contrast, lurasidone has a low affinity for α1 and α2C-adrenergic and 5HT2C serotonin receptors, and no affinity for histaminergic H1 or muscarinic M1 receptors, suggesting a better tolerability profile than the other second-generation antipsychotics. Lurasidone has demonstrated its efficacy in several short-term trials in acute schizophrenia, promptly and significantly reducing total Positive and Negative Syndrome Scale and Brief Psychiatric Rating Scale scores compared with placebo. Several long-term studies are in progress to assess its efficacy in the maintenance treatment of schizophrenic patients. The efficacy of lurasidone with regard to cognitive functions and depressive symptoms seems good, but requires further work. Lurasidone differs from the other second-generation antipsychotics by having a good tolerability profile, in particular for cardiometabolic tolerability. However, it seems to have a significant although moderate link with the occurrence of akathisia, extrapyramidal symptoms, and hyperprolactinemia at the start of treatment. This tolerance profile greatly broadens the scope of second-generation antipsychotics and so supports the view of some authors that the term “second-generation antipsychotic” is now outdated. Other therapeutic perspectives of lurasidone are assessed here, in particular bipolar depression.Keywords: lurasidone, second-generation antipsychotic, schizophrenia, efficacy, safety" @default.
• W2043973417 created "2016-06-24" @default.
• W2043973417 creator A5018075581 @default.
• W2043973417 creator A5029436618 @default.
• W2043973417 creator A5089955461 @default.
• W2043973417 date "2011-06-01" @default.
• W2043973417 modified "2023-10-16" @default.
• W2043973417 title "Clinical potential of lurasidone in the management of schizophrenia" @default.
• W2043973417 cites W1839220452 @default.
• W2043973417 cites W1979797229 @default.
• W2043973417 cites W1993236628 @default.
• W2043973417 cites W1996574538 @default.
• W2043973417 cites W2004055233 @default.
• W2043973417 cites W2019608356 @default.
• W2043973417 cites W2020995975 @default.
• W2043973417 cites W2022808342 @default.
• W2043973417 cites W2026577398 @default.
• W2043973417 cites W2029754105 @default.
• W2043973417 cites W2036534852 @default.
• W2043973417 cites W2045061392 @default.
• W2043973417 cites W2057435138 @default.
• W2043973417 cites W2059022874 @default.
• W2043973417 cites W2060417841 @default.
• W2043973417 cites W2061525750 @default.
• W2043973417 cites W2072587904 @default.
• W2043973417 cites W2078053761 @default.
• W2043973417 cites W2085360366 @default.
• W2043973417 cites W2095721687 @default.
• W2043973417 cites W2096635847 @default.
• W2043973417 cites W2098256072 @default.
• W2043973417 cites W2101228291 @default.
• W2043973417 cites W2101753940 @default.
• W2043973417 cites W2109196233 @default.
• W2043973417 cites W2114258247 @default.
• W2043973417 cites W2119971225 @default.
• W2043973417 cites W2137044087 @default.
• W2043973417 cites W2138418531 @default.
• W2043973417 cites W2151687739 @default.
• W2043973417 cites W2152770536 @default.
• W2043973417 cites W2157007129 @default.
• W2043973417 cites W2159155203 @default.
• W2043973417 cites W2166256285 @default.
• W2043973417 cites W2237018980 @default.
• W2043973417 doi "https://doi.org/10.2147/tcrm.s12701" @default.
• W2043973417 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3132094" @default.
• W2043973417 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21753886" @default.
• W2043973417 hasPublicationYear "2011" @default.
• W2043973417 type Work @default.
• W2043973417 sameAs 2043973417 @default.
• W2043973417 citedByCount "34" @default.
• W2043973417 countsByYear W20439734172012 @default.
• W2043973417 countsByYear W20439734172013 @default.
• W2043973417 countsByYear W20439734172014 @default.
• W2043973417 countsByYear W20439734172015 @default.
• W2043973417 countsByYear W20439734172016 @default.
• W2043973417 countsByYear W20439734172017 @default.
• W2043973417 countsByYear W20439734172018 @default.
• W2043973417 countsByYear W20439734172019 @default.
• W2043973417 countsByYear W20439734172020 @default.
• W2043973417 countsByYear W20439734172021 @default.
• W2043973417 countsByYear W20439734172022 @default.
• W2043973417 countsByYear W20439734172023 @default.
• W2043973417 crossrefType "journal-article" @default.
• W2043973417 hasAuthorship W2043973417A5018075581 @default.
• W2043973417 hasAuthorship W2043973417A5029436618 @default.
• W2043973417 hasAuthorship W2043973417A5089955461 @default.
• W2043973417 hasBestOaLocation W20439734171 @default.
• W2043973417 hasConcept C118552586 @default.
• W2043973417 hasConcept C126322002 @default.
• W2043973417 hasConcept C126855140 @default.
• W2043973417 hasConcept C170493617 @default.
• W2043973417 hasConcept C197934379 @default.
• W2043973417 hasConcept C2775864247 @default.
• W2043973417 hasConcept C2776244919 @default.
• W2043973417 hasConcept C2776412080 @default.
• W2043973417 hasConcept C2776701107 @default.
• W2043973417 hasConcept C2777393122 @default.
• W2043973417 hasConcept C2778375690 @default.
• W2043973417 hasConcept C2779177272 @default.
• W2043973417 hasConcept C2779727114 @default.
• W2043973417 hasConcept C2780135775 @default.
• W2043973417 hasConcept C2780494398 @default.
• W2043973417 hasConcept C2780616385 @default.
• W2043973417 hasConcept C53910766 @default.
• W2043973417 hasConcept C558461103 @default.
• W2043973417 hasConcept C71924100 @default.
• W2043973417 hasConcept C98274493 @default.
• W2043973417 hasConceptScore W2043973417C118552586 @default.
• W2043973417 hasConceptScore W2043973417C126322002 @default.
• W2043973417 hasConceptScore W2043973417C126855140 @default.
• W2043973417 hasConceptScore W2043973417C170493617 @default.
• W2043973417 hasConceptScore W2043973417C197934379 @default.
• W2043973417 hasConceptScore W2043973417C2775864247 @default.
• W2043973417 hasConceptScore W2043973417C2776244919 @default.
• W2043973417 hasConceptScore W2043973417C2776412080 @default.
• W2043973417 hasConceptScore W2043973417C2776701107 @default.
• W2043973417 hasConceptScore W2043973417C2777393122 @default.
• W2043973417 hasConceptScore W2043973417C2778375690 @default.

• next